M2Bio Sciences is a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research. M2Bio’s mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. As one of a handful of companies in the world, M2Bio is actively researching the magic mushroom compound psilocybin by funding research at the University of Pretoria in South Africa. The exploratory research is aiming to discover novel indications for medical conditions such as depression, inflammation, and substance addiction.
In addition, its newly-established private subsidiary, Neur.ai, is developing a portfolio of next-generation receptor agonists based on neurotransformational medicine (also known as psychedelic medicine) for the treatment of mental illness.
The company also owns and operates three cannabis consumer goods brands Medspresso™, Dr. AnnaRx™, and Liviana™. The brands span across a wide range of premium CBD- and mushroom-infused consumer goods including bioceuticals, health and wellness, and precision foods and beverages. With operations currently based in Cape Town, South Africa the company and its brands are positioned in the high-value market segment. In order to position itself within the high-value market segment, M2Bio has had to consistently focus on producing and sourcing the highest-quality ingredients available in the market, from pharmaceutical-grade CBD extract to premium coffees and extra virgin olive oils.